Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

March 4, 2008 updated by: NeurogesX

A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

The purpose of the study is to assess the efficacy, safety and tolerability of NGX 4010 applied for 60 minutes for the treatment of PHN.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

150

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Mesa, Arizona, United States, 85210
        • NeurogesX Investigational Site
      • Peoria, Arizona, United States, 85381
        • NeurogesX Investigational Site
      • Phoenix, Arizona, United States, 85032
        • NeurogesX Investigational Site
    • California
      • Duarte, California, United States, 91010
        • NeurogesX Investigational Site
      • Santa Rosa, California, United States, 95403
        • NeurogesX Investigational Site
    • Florida
      • Boynton Beach, Florida, United States, 33437
        • NeurogesX Investigational Site
      • Bradenton, Florida, United States, 34205
        • NeurogesX Investigational Site
      • Fort Myers, Florida, United States, 33907
        • NeurogesX Investigational Site
      • Naples, Florida, United States, 34102
        • NeurogesX Investigational Site
      • Tampa, Florida, United States, 33614
        • NeurogesX Investigational Site
    • Georgia
      • Atlanta, Georgia, United States, 30328
        • NeurogesX Investigational Site
      • Marietta, Georgia, United States, 30060
        • NeurogesX Investigational Site
    • Massachusetts
      • Brighton, Massachusetts, United States, 02135
        • NeurogesX Investigational Site
    • Missouri
      • St. Louis, Missouri, United States, 63108
        • NeurogesX Investigational Site
      • St. Louis, Missouri, United States, 63141
        • NeurogesX Investigational Site
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • NeurogesX Investigational Site
    • Texas
      • Dallas, Texas, United States, 75235
        • NeurogesX Investigational Site
      • San Antonio, Texas, United States, 78229
        • NeurogesX Investigational Site
    • Utah
      • Salt Lake City, Utah, United States, 84107
        • NeurogesX Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • At least 18 years of age.
  • Be in good health.
  • Diagnosis of postherpetic neuralgia (PHN) made by the primary treating physician or Investigator, and at least 3 months post-vesicle crusting.
  • Screening Pain Sum Score of 12 to 36.
  • Intact, unbroken skin over the painful area(s) to be treated.
  • If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21 days prior to Treatment Visit (Day 0) and willing to maintain medications at same stable dose(s) and schedule throughout the study.
  • Female subjects with child-bearing potential must have a negative serum beta hCG pregnancy test, to be performed at the Screening Visit.
  • All subjects must be willing to use effective methods of birth control and/or refrain from participating in a conception process during the study and for 30 days following experimental drug exposure.
  • Be willing and able to comply with protocol requirements for the duration of study participation. (Such requirements include, but are not limited to: completing a daily pain diary, attending all study visits, and refraining from elective surgery and extensive travel during study participation.)

Exclusion Criteria:

  • Concomitant opioid medication, unless orally or transdermally administered and not exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid use is excluded, regardless of dose.
  • Unavailability of an effective rescue medication strategy for the subject, such as unwillingness to use opioid analgesics during treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort with Roxicodone®, as judged by the Investigator.
  • Active substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse judged likely to recur during the study period by the investigator.
  • Recent use (within 21 days preceding the Treatment Visit [Day 0]) of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin products on the painful areas.
  • Current use of any investigational agent, or Class 1 anti-arrhythmic drugs (such as tocainide and mexiletine).
  • Significant pain of an etiology other than PHN, for example, compression-related neuropathies (e.g., spinal stenosis) or fibromyalgia or arthritis. Subjects must not have significant ongoing pain from other cause(s) that may interfere with judging PHN-related pain.
  • Painful PHN areas located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes. (Investigational treatment with NGX-4010 is not allowed in these areas.)
  • Any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
  • Hypersensitivity to capsaicin (i.e., chili peppers or Over-the-Counter (OTC) capsaicin products), local anesthetics, Roxicodone® or adhesives.
  • Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Masking: Double

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

NeurogesX

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

September 5, 2003

First Submitted That Met QC Criteria

September 8, 2003

First Posted (Estimate)

September 9, 2003

Study Record Updates

Last Update Posted (Estimate)

March 6, 2008

Last Update Submitted That Met QC Criteria

March 4, 2008

Last Verified

September 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C110

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe